{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:58:14Z","timestamp":1792123094601,"version":"4.4.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jdcr.2024.09.027","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T10:35:40Z","timestamp":1731234940000},"page":"33-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature"],"prefix":"10.1016","volume":"56","author":[{"given":"Natalie","family":"Bourand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Kuraitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Lema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2024.09.027_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2024.09.027_bib2","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s13555-024-01198-w","article-title":"Psoriasis in the era of targeted cancer therapeutics: a systematic review on de novo and pre-existing psoriasis in oncologic patients treated with emerging anti-neoplastic agents","volume":"14","author":"Madan","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"10.1016\/j.jdcr.2024.09.027_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.jdcr.2024.09.027_bib4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jdcr.2024.09.027_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdcr.2021.03.015","article-title":"Apremilast for immune checkpoint inhibitor-induced psoriasis: a case series","volume":"11","author":"Mayor Ibarguren","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.jdcr.2024.09.027_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040622318759282","article-title":"Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment","volume":"9","author":"Chan","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jdcr.2024.09.027_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1346687","article-title":"Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors","volume":"15","author":"Morelli","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdcr.2024.09.027_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.03.029","article-title":"Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma","volume":"11","author":"Glinos","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2024.09.027_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-222628","article-title":"Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis","author":"Takeda","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jdcr.2024.09.027_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000875","article-title":"Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma","volume":"33","author":"Gargiulo","year":"2023","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jdcr.2024.09.027_bib11","article-title":"The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: a case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.jdcr.2024.09.027_bib12","first-page":"1","article-title":"The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: a single-institution real-life study","volume":"43","author":"Young","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jdcr.2024.09.027_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf"},{"issue":"7","key":"10.1016\/j.jdcr.2024.09.027_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/exd.13676","article-title":"Inhibition of interleukin-12 and\/or interleukin-23 for the treatment of psoriasis: what is the evidence for an effect on malignancy?","volume":"27","author":"Ergen","year":"2018","journal-title":"Exp Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624004247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624004247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T10:43:01Z","timestamp":1740912181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624004247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":14,"alternative-id":["S2352512624004247"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.027","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}